Inhibition of gastric tumor growth by a novel Hsp90 inhibitor

Biochemical Pharmacology

Volumn 85, Issue 9, 2013, Pages 1246-1256

  Lu, Chunwan ^a,b   Liu, Di ^a   Jin, Jing ^a   Deokar, Hemantkumar ^c   Zhang, Yi ^a   Buolamwini, John K ^c   Yu, Xiaoming ^a   Yan, Chunhong ^b   Chen, Xiaoguang ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b ALBANY MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Cancer therapy; Gastric cancer; Hsp90; Hsp90 inhibitor; Molecular chaperone

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CASPASE 3; CELL CYCLE PROTEIN 37; HEAT SHOCK PROTEIN 90 INHIBITOR; LD 053; PROTEIN KINASE B; RAF PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER INHIBITION; CELL POPULATION; CELL VIABILITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CANCER; WEIGHT REDUCTION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; MICE, NUDE; MODELS, MOLECULAR; NEOPLASM TRANSPLANTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RAF; RESORCINOLS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR BURDEN;

EID: 84875753717     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.02.003     Document Type: Article

References (43)

1. P. Workman, F. Burrows, L. Neckers, and N. Rosen Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress Ann N Y Acad Sci 1113 2007 202 216
2. L. Whitesell, and S.L. Lindquist HSP90 and the chaperoning of cancer Nat Rev Cancer 5 2005 761 772
3. A.W.P. Maloney HSP90 as a new therapeutic target for cancer therapy: the story unfolds Expert Opin Biol Ther 2 2002 3 24
4. L. Neckers, and P. Workman Hsp90 molecular chaperone inhibitors: are we there yet Clin Cancer Res 18 2012 64 76
5. A. Taiyab, and Ch.M. Rao HSP90 modulates actin dynamics: inhibition of HSP90 leads to decreased cell motility and impairs invasion Biochim Biophys Acta 1813 2011 213 221
6. S. Pacey, U. Banerji, I. Judson, and P. Workman Hsp90 inhibitors in the clinic Handb Exp Pharmacol 2006 331 358
7. W. Guo, P. Reigan, D. Siegel, J. Zirrolli, D. Gustafson, and D. Ross Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition Cancer Res 65 2005 10006 10015
8. T. Tsuruo, M. Naito, A. Tomida, N. Fujita, T. Mashima, and H. Sakamoto Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal Cancer Sci 94 2003 15 21
9. Y. Li, T. Zhang, S.J. Schwartz, and D. Sun New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential Drug Resist Updat 12 2009 17 27
10. X. Barril, M.C. Beswick, A. Collier, M.J. Drysdale, B.W. Dymock, and A. Fink 4-Amino derivatives of the Hsp90 inhibitor CCT018159 Bioorg Med Chem Lett 16 2006 2543 2548
11. S.Y. Sharp, K. Boxall, M. Rowlands, C. Prodromou, S.M. Roe, and A. Maloney In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors Cancer Res 67 2007 2206 2216
12. K.M. Cheung, T.P. Matthews, K. James, M.G. Rowlands, K.J. Boxall, and S.Y. Sharp The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors Bioorg Med Chem Lett 15 2005 3338 3343
13. P.A. Brough, W. Aherne, X. Barril, J. Borgognoni, K. Boxall, and J.E. Cansfield 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer J Med Chem 51 2008 196 218
14. R. Howes, X. Barril, B.W. Dymock, K. Grant, C.J. Northfield, and A.G. Robertson A fluorescence polarization assay for inhibitors of Hsp90 Anal Biochem 350 2006 202 213
15. K. Hede Gastric cancer: trastuzumab trial results spur search for other targets J Natl Cancer Inst 101 2009 1306 1307
16. W. Sherman, T. Day, M.P. Jacobson, R.A. Friesner, and R. Farid Novel procedure for modeling ligand/receptor induced fit effects J Med Chem 49 2006 534 553
17. W. Sherman, H.S. Beard, and R. Farid Use of an induced fit receptor structure in virtual screening Chem Biol Drug Des 67 2006 83 84
18. Y. Zhang, H. Li, H. Wang, F. Su, R. Qu, and D. Yin Syl611, a novel semisynthetic taxane derivative, reverses multidrug resistance by p-glycoprotein inhibition and facilitating inward transmembrane action Cancer Chemother Pharmacol 66 2010 851 859
19. H. Wang, M. Jiang, H. Cui, M. Chen, R. Buttyan, and S.W. Hayward The stress response mediator ATF3 represses androgen signaling by binding the androgen receptor Mol Cell Biol 32 2012 3190 3202
20. B.W. Dymock, X. Barril, P.A. Brough, J.E. Cansfield, A. Massey, and E. McDonald Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design J Med Chem 48 2005 4212 4215
21. S.M. Roe, M.M. Ali, P. Meyer, C.K. Vaughan, B. Panaretou, and P.W. Piper The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37) Cell 116 2004 87 98
22. L.H. Pearl Hsp90 and Cdc37 - a chaperone cancer conspiracy Curr Opin Genet Dev 15 2005 55 61
23. M. Bedin, A.M. Gaben, C. Saucier, and J. Mester Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest Int J Cancer 109 2004 643 652
24. P.A. Clarke, I. Hostein, U. Banerji, F.D. Stefano, A. Maloney, and M. Walton Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone Oncogene 19 2000 4125 4133
25. P.N. Meyer, S. Roychowdhury, A.R. Kini, and S. Alkan HSP90 inhibitor 17AAG causes apoptosis in ATRA-resistant acute promyelocytic leukemia cells Leuk Res 32 2008 143 149
26. B. Lamottke, M. Kaiser, M. Mieth, U. Heider, Z. Gao, and Z. Nikolova The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases Eur J Haematol 88 2012 406 415
27. S.X. Wang, H.Q. Ju, K.S. Liu, J.X. Zhang, X. Wang, and Y.F. Xiang SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells Biosci Biotechnol Biochem 75 2011 1540 1545
28. W. Yu, Q. Rao, M. Wang, Z. Tian, D. Lin, and X. Liu The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level Leuk Res 30 2006 575 582
29. H. Wang, H. Li, M. Zuo, Y. Zhang, H. Liu, and W. Fang Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo Cancer Lett 268 2008 89 97
30. L. Neckers Heat shock protein 90: the cancer chaperone J Biosci 32 2007 517 530
31. K.H. Lee, J.H. Lee, S.W. Han, S.A. Im, T.Y. Kim, and D.Y. Oh Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins Cancer Sci 102 2011 1388 1395
32. S.A. Lang, D. Klein, C. Moser, A. Gaumann, G. Glockzin, and M.H. Dahlke Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo Mol Cancer Ther 6 2007 1123 1132
33. L.R. Kelland, S.Y. Sharp, P.M. Rogers, T.G. Myers, and P. Workman DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90 J Natl Cancer Inst 91 1999 1940 1949
34. A.J. Caplan, A.K. Mandal, and M.A. Theodoraki Molecular chaperones and protein kinase quality control Trends Cell Biol 17 2007 87 92
35. K. Terasawa, M. Minami, and Y. Minami Constantly updated knowledge of Hsp90 J Biochem 137 2005 443 447
36. S.D. Hartson, A.D. Irwin, J. Shao, B.T. Scroggins, L. Volk, and W. Huang p50(cdc37) is a nonexclusive Hsp90 cohort which participates intimately in Hsp90-mediated folding of immature kinase molecules Biochemistry 39 2000 7631 7644
37. A. De Luca, M.R. Maiello, A. D'Alessio, M. Pergameno, and N. Normanno The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches Expert Opin Ther Targets 16 Suppl. 2 2012 S17 S27
38. P.P. Roux, and J. Blenis ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions Microbiol Mol Biol Rev 68 2004 320 344
39. M. Baccarini Second nature: biological functions of the Raf-1 kinase FEBS Lett 579 2005 3271 3277
40. S. Meloche, and J. Pouyssegur The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition Oncogene 26 2007 3227 3239
41. A. Taiyab, A.S. Sreedhar, and Ch.M. Rao Hsp90 inhibitors, GA and 17AAG, lead to ER stress-induced apoptosis in rat histiocytoma Biochem Pharmacol 78 2009 142 152
42. H.G. Yu, Y.W. Ai, L.L. Yu, X.D. Zhou, J. Liu, and J.H. Li Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death Int J Cancer 122 2008 433 443
43. U. Maurer, C. Charvet, A.S. Wagman, E. Dejardin, and D.R. Green Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1 Mol Cell 21 2006 749 760